691005-66-0

Upstream product

• 162011-90-7 rofecoxib 

Downstream Products

• 691005-65-9 (+/-)-3-({3-[4-(methylsulfonyl)phenyl]-5-oxo-4-phenyl-2,5-dihydrofuran-2-yl}oxy)benzyl nitrate 
• 691005-64-8 (+/-)-3-[4-(methylsulfonyl)phenyl]-5-oxo-4-phenyl-2,5-dihydrofuran-2-yl nitrate 
• 213763-81-6 2-cyclopropylmethyl-5-(4-methylsulfonyl)phenyl-4-phenyl-2H-pyridazin-3-one 
• 213764-15-9 5-(4-methylsulfonyl)phenyl-4-phenyl-2H-pyridazin-3-one 
• 185147-17-5 5-Hydroxyrofecoxib 

Relevant academic research and scientific papers

Pyridazinones as selective cyclooxygenase-2 inhibitors

Pyridazinone was found to be an excellent core template for selective COX-2 inhibitors. Two potent, selective and orally active COX-2 inhibitors, which were highly efficacious in rat paw edema and rat pyresis models, have been obtained.

NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS

The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H) furanones useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions and methods for treatment of cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula I. The above compounds may be used as a combination therapy with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions while simultaneously reducing the risk of thrombotic cardiovascular events.